Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome

Gynecological Endocrinology

Volumn 25, Issue 5, 2009, Pages 335-343

  Fruzzetti, Franca ^a   Perini, Daria ^a   Lazzarini, Veronica ^a   Parrini, Donatella ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adolescence; Hyperandrogenism; Metabolic syndrome; PCOS

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; BODY MASS; CARDIOVASCULAR RISK; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; OBESITY; OUTPATIENT DEPARTMENT; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL; UNIVERSITY HOSPITAL;

ADOLESCENT; COMORBIDITY; FEMALE; HUMANS; HYPERANDROGENISM; ITALY; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67651124853     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802630146     Document Type: Article

References (49)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implication for pathogenesis. Endocr Rev 1997;18:774-800.
5. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-951.
6. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-613.
7. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007;18:280-285.
8. Berneis K, Rizzo M, Fruzzetti F, Lazzarini V, Carmina E. Atherogenic lipoprotein phenotype and low density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:186-189.
9. Shaw LJ, Bairey CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the national institutes of health-national heart, lung, and blood institute sponsored women's ischemia syndrome. Evaluation. J Clin Endocrinol Metab 2008;93:1276-1284.
10. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286:2421-2426.
11. Glueck CJ, Morrison JA, Friedman LA, Goldenberg N, Stroop DM, Wang P. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism 2006;55:508-514.
12. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoǧlu G, Yesilkaya E, Hasanoglu A. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;67:129-134.
13. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740-2746.
14. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril, 2008 Aug 13.
15. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 2007;18:774-800.
16. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25-29.
17. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-722.
18. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
19. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk factor and life expectancy research group. Am J Epidemiol 1998;48:958-966.
20. Haffner SM, D'Agostino R Jr, Festa A, Bergman RN, Karter A, Saad MF, Wagenknecht LE. Low insulin sensitivity in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 2003;26:2796-2803.
21. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
22. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-915.
23. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131-137.
24. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Clin Invest 2006;29:270-280.
25. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-497.
26. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. pp 377-384.
27. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus Workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Sterl 2004;81:19-25.
28. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006;29:581-593.
29. Fernández JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004;145:439-444.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insuline resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentrations of low density lipoprotein cholesterol without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
32. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the third national health and nutrition examination survey. Circulation 2004;110:2494-2497.
33. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-576.
34. Apter D, Vihko R. Premenarcheal endocrine changes in relation to age at menarche. Clin Endocrinol 22:753-760.
35. Venturoli S, Porcu E, Fabbri R, Magrini O, Paradisi R, Pallotti G, Gammi L, Flamigni C. Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities. Fertil Steril 1987;48:78-85.
36. Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 2006;1092:158-174. Review.
37. Jeffrey Chang R, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 2007;50: 178-187.
38. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: 787-796.
39. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821-827.
40. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374.
41. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004;89:108-113.
42. Frontini MG, Srinivasan SR, Berenson GS. Longitudinal changes in risk variables underlying metabolic syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2003;27:1398-1404.
43. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan LM. Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr 2004;145: 445-451.
44. Carmina E, Napoli N, Longo RA, Rini GB, Lobo R. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006;154:141-145.
45. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20:2409-2413.
46. Carmina E, Chu MC, Longo A, Rini GB, Lobo R. Phenotypic variations in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-2549.
47. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007;18:280-285.
48. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatoryday-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 2003;11:23-28.
49. Mei-Jou C, Wei-Shiung Y, Jehn-Hsiahn Y, Chi-Ling, Hong-Nerng H, Yu-Shih Y. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007;49:1442-1447.